MPE launches the Myeloma and AL Amyloidosis European Clinical Trial NavigatorAccess, AL amyloidosis, MPE, MyelomaApril 23, 2024
European Commission approves CAR T-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory myelomaAccess, CAR-T, MyelomaApril 23, 2024
New clinical trial to evaluate the myeloma drug selinexor as potential treatment for patients with COVID-19MyelomaApril 14, 2020
Ana Rocha, young myeloma patient: “I didn’t let the diagnosis change me and I thought I should build something to help others newly diagnosed”MPE, MyelomaMarch 8, 2024
Snežana Doder, young myeloma patient: “When I talk about my journey, I compare it to a roller coaster. Everything happened very fast and unexpectedly”MPE, MyelomaMarch 25, 2024
ASCO and EHA highlights in myeloma and AL amyloidosisAL amyloidosis, Conferences, MPE, Myeloma, VideosJuly 20, 2020
The FDA approves the first anti-BCMA CAR-T Cell Therapy for myeloma, idecabtagene vicleucel (Abecma)Access, MyelomaMarch 31, 2021
Horizon2020 CARAMBA Myeloma Pipeline information sheet now available in five languagesMPE, MyelomaApril 7, 2021
Impact of the COVID-19 pandemic on the healthcare and lives of myeloma or AL amyloidosis patients and their caregiversAL amyloidosis, MPE, Myeloma, Patient evidenceJune 21, 2021
